Welcome to our dedicated page for Alaunos Therapeutics news (Ticker: TCRT), a resource for investors and traders seeking the latest updates and insights on Alaunos Therapeutics stock.
Alaunos Therapeutics, Inc. (TCRT) is a clinical-stage leader developing TCR-T cell therapies targeting neoantigens in solid tumors. This page provides centralized access to all material updates from this innovator in precision immuno-oncology.
Investors and researchers will find essential announcements including clinical trial progress, regulatory milestones, and scientific collaborations. Our curated feed ensures timely access to verified updates on therapeutic developments and corporate strategy.
Key content areas include updates on TCR-T platform advancements, partnership announcements with research institutions, and financial disclosures. All information is sourced directly from company filings and authorized communications.
Bookmark this page for efficient tracking of Alaunos' pioneering work in targeting RAS-mutant cancers and other genomic drivers. Check regularly for developments in their mission to transform solid tumor treatment through engineered cellular therapies.
Alaunos Therapeutics (TCRT) announced its acceptance to present a talk at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference (CICON) in New York from September 28 – October 1, 2022.
The presentation titled "Objective clinical response by KRAS mutation-specific TCR-T cell therapy in previously treated advanced Non-small cell lung cancer" will be delivered by Dr. Marcelo V. Negrao on September 30, 2022, at 8:30 am ET.
Alaunos specializes in oncology-focused cell therapies and has a collaboration with the National Cancer Institute.
Alaunos Therapeutics (TCRT) announced their Phase 1/2 trial targeting KRAS, TP53, and EGFR mutations in solid tumors is actively enrolling patients. The company has appointed Abhishek Srivastava, Ph.D., as VP, Technical Operations, and extended its collaboration with the National Cancer Institute until 2025. Financially, Alaunos reported a 62% decrease in operating cash burn for Q2 2022 to $8.2 million, and a net loss of $9.9 million or $(0.05) per share. The company expects its cash runway to fund operations until Q2 2023.
Alaunos Therapeutics, Inc. (Nasdaq: TCRT) has appointed Dr. Abhishek Srivastava as Vice President of Technical Operations, effective immediately. Dr. Srivastava's role will focus on enhancing manufacturing operations, process optimization, and capacity expansion. With over 15 years of experience in cell therapy, he previously worked at Athenex and the University of Pittsburgh. This appointment comes as Alaunos advances its TCR T Library Phase 1/2 trial, leveraging its proprietary Sleeping Beauty technology. CEO Kevin Boyle expresses confidence in Dr. Srivastava’s ability to drive operational efficiency.
Alaunos Therapeutics, Inc. (Nasdaq: TCRT) has announced an extension of its Cooperative Research and Development Agreement with the National Cancer Institute (NCI) to January 2025. This agreement will utilize Alaunos’ proprietary non-viral Sleeping Beauty technology to develop personalized T-cell receptor (TCR) therapies. The partnership aims to create safe and effective TCR-T therapies for solid tumor cancer patients. Alaunos is confident that this collaboration will enhance their TCR-T platforms and increase the potential patient population for these therapies.
CellChorus Inc. has established a scientific advisory board featuring experts Rebecca Berdeaux, PhD, Dimitrios Kontoyiannis, MD, PhD, and Laurence Cooper, MD, PhD. This board aims to promote the application of the company’s TIMING™ platform in various therapeutic areas, enhancing patient care. Dr. Berdeaux emphasizes the significance of single-cell analysis, while Dr. Cooper brings leadership experience from Alaunos Therapeutics and MD Anderson Cancer Center. The advisory board is expected to support CellChorus in expanding into new clinical applications.
Alaunos Therapeutics (TCRT) announces its participation in the Jefferies 2022 Global Healthcare Conference. The event is scheduled for June 10, 2022, from 9:00-9:25 am ET at the New York Marriott Marquis, Track 6. CEO Kevin S. Boyle Sr. and VP of R&D Drew Deniger, Ph.D. will present. A live webcast will be available on the company's website, with a replay accessible for 90 days post-event. Alaunos focuses on oncology cell therapies utilizing proprietary T-cell receptor technology, collaborating with leading institutes like MD Anderson and the National Cancer Institute.
Alaunos Therapeutics (TCRT) announced a Trials in Progress poster presentation at the 2022 ASCO Annual Meeting, scheduled from June 3-7, 2022. The presentation will cover the adaptive trial design for their ongoing TCR-T Library Phase 1/2 trial at MD Anderson Cancer Center, targeting various cancers with specific HLA and mutation pairings. The first patient has been dosed in the trial, which aims to utilize the company's proprietary Sleeping Beauty technology. Initial data is anticipated later this year as patient enrollment continues.
Alaunos Therapeutics (TCRT) announced the successful dosing of its first patient in the TCR-T Library Phase 1/2 trial targeting specific mutations in solid tumors. This milestone highlights the use of its proprietary non-viral TCR-T technology. The trial, conducted at MD Anderson Cancer Center, will evaluate safety and define dosage for patients with various cancers. Financially, Q1 2022 net loss decreased to $9.8 million from $21.6 million in Q1 2021, alongside a significant reduction in R&D and G&A expenses, attributed to cost-cutting measures. Cash reserves totaled $68.3 million, expected to last into Q2 2023.
Alaunos Therapeutics (Nasdaq: TCRT) will present at the H.C. Wainwright Global Investment Conference on May 24, 2022, from 5:00-5:30 PM ET at the Fontainebleau Miami Beach Hotel. The presentation will be delivered by CEO Kevin S. Boyle Sr. and VP of R&D Drew Deniger, Ph.D. A live webcast will be available on the company's website, with replays accessible for 90 days. Alaunos focuses on T-cell receptor therapies for oncology, utilizing its proprietary Sleeping Beauty gene transfer technology and collaborating with leading cancer research institutions.
Alaunos Therapeutics (TCRT) is set to announce its financial results for the first quarter ending March 31, 2022, on May 16, 2022, before U.S. market opening. A conference call will follow at 8:30 a.m. ET to discuss the results and provide a corporate update. Interested parties can join via phone or live webcast, with the event archived for 30 days post-call. Alaunos focuses on developing T-cell receptor therapies using proprietary gene transfer technology, with collaborations with MD Anderson Cancer Center and the National Cancer Institute.
